37 reports of this reaction
1.8% of all NORETHINDRONE AND ETHINYL ESTRADIOL reports
#11 most reported adverse reaction
PULMONARY EMBOLISM is the #11 most commonly reported adverse reaction for NORETHINDRONE AND ETHINYL ESTRADIOL, manufactured by Teva Pharmaceuticals USA, Inc.. There are 37 FDA adverse event reports linking NORETHINDRONE AND ETHINYL ESTRADIOL to PULMONARY EMBOLISM. This represents approximately 1.8% of all 2,014 adverse event reports for this drug.
Patients taking NORETHINDRONE AND ETHINYL ESTRADIOL who experience pulmonary embolism should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY EMBOLISM is a less commonly reported adverse event for NORETHINDRONE AND ETHINYL ESTRADIOL, but still significant enough to appear in the safety profile.
In addition to pulmonary embolism, the following adverse reactions have been reported for NORETHINDRONE AND ETHINYL ESTRADIOL:
The following drugs have also been linked to pulmonary embolism in FDA adverse event reports:
PULMONARY EMBOLISM has been reported as an adverse event in 37 FDA reports for NORETHINDRONE AND ETHINYL ESTRADIOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY EMBOLISM accounts for approximately 1.8% of all adverse event reports for NORETHINDRONE AND ETHINYL ESTRADIOL, making it a notable side effect.
If you experience pulmonary embolism while taking NORETHINDRONE AND ETHINYL ESTRADIOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.